News

Most healthcare players agree that ICD-10 implementation will be expensive and resource-intensive. Yet opportunities abound to enable proactive organizations to become industry leaders with the new system.

Washington, D.C. - The Bush administration has proposed additional curbs on certain sales practices by insurers likely to confuse and deceive seniors enrolling in Medicare Advantage and prescription drug plans. Insurers applauded the marketing policy, partly in hopes of heading off legislation that would give states a larger role in policing Medicare marketing activities.

How is it that well-informed people can look at the same data and come up with dramatically different conclusions and action implications? It turns on whether the analysis is done by biostatisticians looking at utilization data in an academically rigorous way, or by actuaries and benefits consultants looking at overall financial trends in a pre-post manner.

The use of technology to automate simple tasks has been widely adopted. E-mails broadcast information in a fraction of the time it would take a manual process. More complex tasks, however, require a human driver, and those tasks are in higher demand today.

The intensive care unit (ICU) is, in many ways, the most significant section of a hospital, because it is where life-threatening issues occur almost daily. The ICU is the one area where most hospitals don't employ specialists-board-certified intensivists with expertise and training in critical care medicine.

When companies interact with governmental bodies, issues related to the Public Information Act frequently arise. It is imperative for those companies to understand the Public Information Act as well as the internal procedures that may be developed to handle open records issues.

I had the honor of joining 40 executive delegates for a week to observe the Irish healthcare system. While spending in the Irish healthcare system is just 7.2% of GDP, the public hospitals are filled to the gills.

Adding zoledronic acid to anastrozole or tamoxifen therapy decreased recurrence by 35% and increased disease free survival by 36% in premenopausal breast cancer patients, according to results of the Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12). The multicenter, Phase III trial is the first large trial to demonstrate the significant antitumor benefit of zoledronic acid, said Michael Gnant, MD, Medical University of Vienna. "Adjuvant treatment with zoledronic acid should be considered in order to improve the standard of care in premenopausal breast cancer patients," he said.

Adherence to a four-point Individualized Sleep Promotion Plan (ISPP) intervention consisting of stimulus control, sleep restriction, relaxation therapy, and sleep-hygiene practices significantly lowered fatigue and increased sleep quality for patients undergoing adjuvant chemotherapy. Fatigue and sleep disturbances are the most frequently reported symptoms during adjuvant chemotherapy for breast cancer. One-third of breast cancer patients report persistent fatigue and abnormal sleep/wake cycles, said Ann M Berger, PhD, RN, professor, College of Nursing, University of Nebraska Medical Center, Omaha.

Phase 3 trial results show that adding bevacizumab to docetaxel as first-line therapy for newly diagnosed HER2-negative, locally recurrent, or metastatic breast cancer resulted in significantly less disease progression. "This shows that the antiangiogenic approach to treating breast cancer is effective, regardless of which taxane drug it is combined with," said lead author David Miles, MD, professor, Mount Vernon Cancer Center, Middlesex, UK. Previous studies have shown that the combination of bevacizumab to paclitaxel doubled progression-free survival among patients with metastatic breast cancer.

Cancer is an independent predictor of increased vulnerability, functional limitations, geriatric syndromes, frailty, and fair or poor health status among older Medicare beneficiaries. "Up until now, a lot of this has been more opinion rather than numbers," said Gary R. Morrow, MD, professor of radiation oncology, University of Rochester Cancer Center. "This gives us a method to let us know if we have changed anything.

National News-Small businesses are less likely to offer employee health benefits, especially if they’re the new kid on the block, according to a recent report from the Kaiser Family Foundation. Analysis finds that among firms with nine employees or fewer, those in business for 20 years or more are more likely to offer benefits.

Cleveland-Cleveland Clinic has its own electronic personal health record system for patient viewing, and now it plans to pilot information-exchange capabilities with GoogleHealth, an online PHR platform.

Oakland, Calif.-Nearly 9 million Kaiser Permanente members in nine states are now on the books with the plan’s HealthConnect electronic medical record system, which completed a four-year rollout recently. Installation cost $4 billion, including $1 billion for maintenance.

National News-Wal-Mart will offer generic medications for $10 for a 90-day supply, which previously cost $4 for a 30-day supply, offering more over-the-counter medications at $4. About 350 generics are covered. At the same time, Target’s prescription drug program now includes an expanded assortment of $4 prescription drugs, 90-day supply of these medications for $10 and OTC medications for $4 or less.

Washington, D.C.-There’s a lot of talk in Washington about the importance of enacting legislation to establish a pathway for FDA to approve “similar” or “follow-on” versions of biotech drugs. Biopharmaceutical companies have been pushing for compromise legislation this year, that is aligned with health insurers, pharmacy benefit managers, and public and private payers, who envision big savings.